Summary & Overview
Hip Replacement with Principal Diagnosis of Hip Fracture without MCC: Inpatient Reimbursement Overview
DRG 522 applies to inpatient hip replacement for patients with a principal diagnosis of hip fracture without Major Complication or Comorbidity; it defines the clinical population and expected inpatient resource use. This Diagnosis-Related Group is important for inpatient reimbursement because it determines the bundled Medicare payment level and influences documentation and coding that affect hospital payment.
DRG 522 Overview
DRG 522 covers inpatient admissions for hip replacement when the principal diagnosis is a hip fracture and there is no Major Complication or Comorbidity present. This Diagnosis-Related Group captures cases where surgical repair or replacement of the hip is performed for fracture without the added resource intensity of major comorbid conditions. It matters for Medicare payment because the Diagnosis-Related Group assignment drives the bundled prospective payment for the inpatient stay. Accurate coding of the principal diagnosis and secondary conditions determines whether this Diagnosis-Related Group, a lower-paying fracture replacement category, is assigned instead of higher-paying groups with complication indicators.
Clinical Trials
- Acute perioperative optimization trials: Studies focusing on immediate surgical and anesthetic strategies for older adults undergoing hip replacement for acute hip fracture, such as protocols comparing regional versus general anesthesia approaches, blood management strategies, and perioperative infection prevention bundles. These trials enroll frail, often comorbid elderly patients admitted with an acute displaced femoral neck or intertrochanteric fracture who are scheduled for arthroplasty, and they measure short-term outcomes like surgical complications, length of stay, in-hospital mortality, and early functional recovery. This research is relevant to providers and payers because optimizing the acute inpatient pathway can reduce complications and resource use during the high-cost index hospitalization captured by this DRG.
- Comparative effectiveness and device/technique studies in implant selection and surgical approach: Randomized or pragmatic comparative studies testing different prosthesis designs, fixation methods (cemented versus cementless), or surgical approaches (posterior, lateral, anterior) specifically in patients receiving hip replacement for fracture rather than elective osteoarthritis. These studies target the fracture-specific population, who differ from elective arthroplasty patients in bone quality, urgency of surgery, and rehabilitation potential, and evaluate outcomes such as implant stability, reoperation rates, postoperative mobility, and early adverse events. Findings inform surgeons and payers about which approaches produce better short- and medium-term outcomes and lower readmission or revision risk, affecting device utilization and bundled payment considerations.
- Post-discharge recovery, rehabilitation, and health services outcome studies: Cohort studies or randomized trials examining inpatient-to-postacute care transitions, timing/intensity of physical therapy, models of home-based versus skilled nursing rehabilitation, and interventions to reduce readmissions and improve functional independence among hip fracture arthroplasty patients. These studies focus on older adults with varying pre-fracture functional status and comorbidities, assessing outcomes like 30- and 90-day readmissions, discharge disposition, functional scores, and cost-effectiveness across care settings. Results are crucial for payers and hospital systems designing discharge pathways and postacute networks to improve recovery, control post-discharge costs, and optimize value for patients assigned to this DRG.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.